Attrition in the Pharmaceutical Industry: Reasons, Implications, and Pathways Forward - Hardcover

Alex, Alexander; Harris, C. John; Smith, Dennis A.

Hardcover

ISBN 10: 1118679679 ISBN 13: 9781118679678

Publisher: Wiley, 2015

Synopsis

With a focus on case studies of R&D programs in a variety of disease areas, the book highlights fundamental productivity issues the pharmaceutical industry has been facing and explores potential ways of improving research effectiveness and efficiency.

· Takes a comprehensive and holistic approach to the problems and potential solutions to drug compound attrition
· Tackles a problem that adds billions of dollars to drug development programs and health care costs
· Guides discovery and development scientists through R&D stages, teaching requirements and reasons why drugs can fail
· Discusses potential ways forward utilizing new approaches and opportunities to reduce attrition

About this title

From the Back Cover:

Compound attrition in drug discovery and development is one of the major challenges the pharmaceutical industry has faced over the last two decades, with an insufficient number of revenue-generating new drugs in recent years leading to misaligned investments in research and development. Additionally, the value of existing data and knowledge has been neglected – leading to insufficient learning from drug programs and inevitable repeat of poor results. A further reluctance to utilize new technologies, like advances in IT and data management, has led to many companies being unable to convert data archives into useful knowledge to improve productivity.

Arising from the need to meet these problems, Attrition in the Pharmaceutical Industry tackles the problem of drug compound attrition, which adds billions of dollars to drug development programs and health care costs. With a focus on case studies of R&D programs in a variety of disease areas, the book highlights fundamental productivity issues the pharmaceutical industry has been facing and explores potential ways of improving research effectiveness and efficiency, providing valuable strategies and guidance for decision makers across drug development.

Written by contributing authors on the frontlines of the drug research and development community, this book offers a number of key benefits that include:

· A comprehensive and holistic approach to the problems and potential solutions to drug compound attrition
· Guidance for discovery and development scientists through R&D stages, teaching requirements and reasons why drugs can fail
· Discussion of potential ways forward utilizing new approaches and opportunities to reduce attrition

About the Author:

Alexander Alex, Dr. rer. nat., is director of Evenor Consulting and has over 20 years’ experience as consultant and as director and research fellow in drug discovery in the pharmaceutical industry.

C. John Harris, PhD, is the director of cjh Consultants and has a successful track record in drug discovery, research management, small company fund-raising and start-ups.

Dennis A. Smith, PhD, is an independent consultant with a long track record in drug discovery and development with an emphasis on metabolism and safety. He has published four books, including Pharmacokinetics and Metabolism in Drug Design (1st and 2nd editions) and Reactive Drug Metabolites published by Wiley.

About this edition

• Publisher: Wiley
• Publication date: 2015
• ISBN 10: 1118679679
• ISBN 13: 9781118679678
• Binding: Hardcover
• Edition number: 1
• Number of pages: 370